These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

511 related items for PubMed ID: 34658264

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU, Hutt DF, Rowczenio D, Gilbertson J, Martinez-Naharro A, Venneri L, Whelan C, Lachmann H, Wechalekar A, Quarta CC, Merlo M, Sinagra G, Hawkins PN, Fontana M, Gillmore JD.
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [Abstract] [Full Text] [Related]

  • 3. Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry.
    Parker MM, Damrauer SM, Tcheandjieu C, Erbe D, Aldinc E, Hawkins PN, Gillmore JD, Hull LE, Lynch JA, Joseph J, Ticau S, Flynn-Carroll AO, Deaton AM, Ward LD, Assimes TL, Tsao PS, Chang KM, Rader DJ, Fitzgerald K, Vaishnaw AK, Hinkle G, Nioi P.
    Sci Rep; 2021 Jun 02; 11(1):11645. PubMed ID: 34079032
    [Abstract] [Full Text] [Related]

  • 4. Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation.
    Tini G, Vianello PF, Gemelli C, Grandis M, Canepa M.
    J Cardiovasc Transl Res; 2019 Dec 02; 12(6):514-516. PubMed ID: 30604309
    [Abstract] [Full Text] [Related]

  • 5. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
    Coelho T, Maurer MS, Suhr OB.
    Curr Med Res Opin; 2013 Jan 02; 29(1):63-76. PubMed ID: 23193944
    [Abstract] [Full Text] [Related]

  • 6.
    Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Sekijima Y, Nakamura K.
    ; 1993 Jan 02. PubMed ID: 20301373
    [Abstract] [Full Text] [Related]

  • 7. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF, Hahn K.
    Inn Med (Heidelb); 2023 Sep 02; 64(9):848-854. PubMed ID: 37555967
    [Abstract] [Full Text] [Related]

  • 8. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
    Waddington-Cruz M, Ackermann EJ, Polydefkis M, Heitner SB, Dyck PJ, Barroso FA, Wang AK, Berk JL, Dyck PJB, Monia BP, Hughes SG, Tai L, Jesse Kwoh T, Jung SW, Coelho T, Benson MD, Gertz MA.
    Amyloid; 2018 Sep 02; 25(3):180-188. PubMed ID: 30169969
    [Abstract] [Full Text] [Related]

  • 9. A novel TTR mutation (p.Ala65Val) underlying late-onset hereditary transthyretin (ATTRv) amyloidosis with mixed cardiac and neuropathic phenotype: a case report.
    Thimm A, Oubari S, Hoffmann J, Carpinteiro A, Papathanasiou M, Luedike P, Kessler L, Rischpler C, Röcken C, Diebold I, Rassaf T, Schmidt H, Kleinschnitz C, Hagenacker T.
    BMC Neurol; 2022 Dec 09; 22(1):469. PubMed ID: 36494773
    [Abstract] [Full Text] [Related]

  • 10. Three patients of transthyretin amyloidosis in a Japanese family with amyloidogenic transthyretin Thr49Ser (p.Thr69Ser) variant.
    Ikura H, Kitakata H, Endo J, Moriyama H, Sano M, Tsujikawa H, Sawano M, Masuda T, Ohki T, Ueda M, Kosaki K, Fukuda K.
    Eur J Med Genet; 2022 Mar 09; 65(3):104451. PubMed ID: 35149236
    [Abstract] [Full Text] [Related]

  • 11. Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management.
    Alcantara M, Mezei MM, Baker SK, Breiner A, Dhawan P, Fiander A, Fine NM, Hahn C, Katzberg HD, Khayambashi S, Massie R, Matte G, Putko B, Siddiqi Z, Delgado D, Bril V.
    Can J Neurol Sci; 2022 Jan 09; 49(1):7-18. PubMed ID: 33631091
    [Abstract] [Full Text] [Related]

  • 12. [Late-onset hereditary transthyretin amyloidosis with polyneuropathy. Report of one case].
    Matamala JM, Peña C, Moreno-Roco J, Álvarez J, Villegas P, Stuardo A, Puga B, Valjalo R, Correa G, Jeraldo C, Méndez G, Larrondo J, Gosch M, Carrasco R.
    Rev Med Chil; 2022 Sep 09; 150(9):1260-1265. PubMed ID: 37358138
    [Abstract] [Full Text] [Related]

  • 13. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays.
    Kaku MC, Bhadola S, Berk JL, Sanchorawala V, Connors LH, Lau KHV.
    Amyloid; 2022 Sep 09; 29(3):184-189. PubMed ID: 35253562
    [Abstract] [Full Text] [Related]

  • 14. Hereditary transthyretin-related amyloidosis.
    Finsterer J, Iglseder S, Wanschitz J, Topakian R, Löscher WN, Grisold W.
    Acta Neurol Scand; 2019 Feb 09; 139(2):92-105. PubMed ID: 30295933
    [Abstract] [Full Text] [Related]

  • 15. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
    Gertz MA, Scheinberg M, Waddington-Cruz M, Heitner SB, Karam C, Drachman B, Khella S, Whelan C, Obici L.
    Expert Rev Clin Pharmacol; 2019 Aug 09; 12(8):701-711. PubMed ID: 31268366
    [Abstract] [Full Text] [Related]

  • 16. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A, Vela P, de Frutos F, Mora N, Pomares A, Gonzalez-Vioque E, Briceño A, Cabrera E, Cobo-Marcos M, Dominguez F, Gonzalez-Lopez E, Segovia J, Lara-Pezzi E, Garcia-Pavia P.
    Eur J Heart Fail; 2022 Dec 09; 24(12):2367-2373. PubMed ID: 35999650
    [Abstract] [Full Text] [Related]

  • 17. DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis.
    Akinboboye O, Shah K, Warner AL, Damy T, Taylor HA, Gollob J, Powell C, Karsten V, Vest J, Maurer MS.
    Amyloid; 2020 Dec 09; 27(4):223-230. PubMed ID: 32456532
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.